2023
DOI: 10.1152/ajprenal.00232.2023
|View full text |Cite
|
Sign up to set email alerts
|

Angiotensin II hypertension along the female rat tubule: predicted impact on coupled transport of Na+ and K+

Aurélie Edwards,
Donna L. Ralph,
Adriana Mercado
et al.

Abstract: Chronic infusion of subpressor level of Angiotensin II (AngII) increases the abundance of Na+ transporters along the distal nephron, balanced by suppression of Na+ transporters along the proximal tubule and medullary thick ascending limb (defined as proximal nephron), which impacts K+ handling along the entire renal tubule. The objective of this study was to quantitatively assess the impact of chronic AngII on the renal handling of Na+ and K+ in female rats, using a computational model of the female rat renal … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 68 publications
0
1
0
Order By: Relevance
“…At present, there’s a lack of consensus regarding the optimal diabetic medication for individuals with GS, with insufficient data on the potential adverse effects of various hypoglycemic agents on this condition. Research indicates that SGLT2 inhibitors could potentially reduce hyperkalemia incidence without exacerbating hypokalemia ( Ferreira et al, 2022 ; Edwards et al, 2023 ). SGLT2 inhibitors are recognized for their cardioprotective and nephroprotective properties, thus making them particularly advantageous for patients at high risk of cardiovascular diseases and those suffering from chronic kidney disease ( Zelniker et al, 2019 ; Rahman et al, 2023 ).…”
Section: Discussionmentioning
confidence: 99%
“…At present, there’s a lack of consensus regarding the optimal diabetic medication for individuals with GS, with insufficient data on the potential adverse effects of various hypoglycemic agents on this condition. Research indicates that SGLT2 inhibitors could potentially reduce hyperkalemia incidence without exacerbating hypokalemia ( Ferreira et al, 2022 ; Edwards et al, 2023 ). SGLT2 inhibitors are recognized for their cardioprotective and nephroprotective properties, thus making them particularly advantageous for patients at high risk of cardiovascular diseases and those suffering from chronic kidney disease ( Zelniker et al, 2019 ; Rahman et al, 2023 ).…”
Section: Discussionmentioning
confidence: 99%